Cargando…
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease
The presence of cirrhosis in nonalcoholic-fatty-liver-disease (NAFLD) is the most important predictor of liver-related mortality. Limited data exist concerning the diagnostic accuracy of gut-microbiome-derived signatures for detecting NAFLD-cirrhosis. Here we report 16S gut-microbiome compositions o...
Autores principales: | Caussy, Cyrielle, Tripathi, Anupriya, Humphrey, Greg, Bassirian, Shirin, Singh, Seema, Faulkner, Claire, Bettencourt, Ricki, Rizo, Emily, Richards, Lisa, Xu, Zhenjiang Z., Downes, Michael R., Evans, Ronald M., Brenner, David A., Sirlin, Claude B., Knight, Rob, Loomba, Rohit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440960/ https://www.ncbi.nlm.nih.gov/pubmed/30926798 http://dx.doi.org/10.1038/s41467-019-09455-9 |
Ejemplares similares
-
Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls
por: Patel, Niraj S., et al.
Publicado: (2013) -
Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020) -
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
por: Dufour, Jean-François, et al.
Publicado: (2020) -
Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease
por: Ajmera, Veeral, et al.
Publicado: (2022) -
Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)